AutoCyte Moves One Step Closer To FDA Approval

CEO SUMMARY: Until now, AutoCyte has kept a relatively quiet presence in the automated cytology marketplace. That may soon change as the FDA takes action on the company’s PREP™ and SCREEN™ products. AutoCyte expects these products will boost productivity and quality in cytology labs. AutoCyte’s product positioning will be very different than its competitors: NeoPath, …

AutoCyte Moves One Step Closer To FDA Approval Read More »

To access this post, you must purchase The Dark Report.

AutoCyte Moves One Step Closer To FDA Approval

AutoCyte needs FDA decision to become newest competitor in automated cytology

Comments

TABLE OF CONTENTS

Need A Group Membership? Company Discounts are Available!

You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

You have read 0 of 1 of your complimentary articles this month